Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond Sanchez

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Psychiatry|September 5, 2014
Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled studyJohn M Kane, Timothy Peters-Strickland, Ross A Baker, et al.
Journal of Affective Disorders|August 27, 2018
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal studyJoseph R Calabrese, Raymond Sanchez, Na Jin, et al.
The Journal of Clinical Psychiatry|February 2, 2017
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal StudyJoseph R Calabrese, Raymond Sanchez, Na Jin, et al.
Schizophrenia Research|October 6, 2014
Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studiesW Wolfgang Fleischhacker, Ross A Baker, Anna Eramo, et al.
Clinical Schizophrenia & Related Psychoses|February 26, 2015
Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind StudiesJohn M Kane, Raymond Sanchez, Ross A Baker, et al.
Lancet (London, England)|December 17, 2022
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trialJohn H Krystal, John M Kane, Christoph U Correll, et al.
The British Journal of Psychiatry : the Journal of Mental Science|June 14, 2014
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority studyW Wolfgang Fleischhacker, Raymond Sanchez, Pamela P Perry, et al.
The Lancet. Neurology|July 15, 2026
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trialHubert H Fernandez, Perminder Bhatia, Leslie Cloud, et al.
JAMA Neurology|March 20, 2026
Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical TrialRajesh Pahwa, Elena Moro, Alberto J Espay, et al.
JAMA Neurology|March 20, 2026
Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical TrialHubert H Fernandez, Stuart H Isaacson, Robert A Hauser, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Psychiatry|September 5, 2014
Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled studyJohn M Kane, Timothy Peters-Strickland, Ross A Baker, et al.
Journal of Affective Disorders|August 27, 2018
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal studyJoseph R Calabrese, Raymond Sanchez, Na Jin, et al.
The Journal of Clinical Psychiatry|February 2, 2017
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal StudyJoseph R Calabrese, Raymond Sanchez, Na Jin, et al.
Schizophrenia Research|October 6, 2014
Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studiesW Wolfgang Fleischhacker, Ross A Baker, Anna Eramo, et al.
Clinical Schizophrenia & Related Psychoses|February 26, 2015
Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind StudiesJohn M Kane, Raymond Sanchez, Ross A Baker, et al.
Lancet (London, England)|December 17, 2022
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trialJohn H Krystal, John M Kane, Christoph U Correll, et al.
The British Journal of Psychiatry : the Journal of Mental Science|June 14, 2014
Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority studyW Wolfgang Fleischhacker, Raymond Sanchez, Pamela P Perry, et al.
The Lancet. Neurology|July 15, 2026
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trialHubert H Fernandez, Perminder Bhatia, Leslie Cloud, et al.
JAMA Neurology|March 20, 2026
Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical TrialRajesh Pahwa, Elena Moro, Alberto J Espay, et al.
JAMA Neurology|March 20, 2026
Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical TrialHubert H Fernandez, Stuart H Isaacson, Robert A Hauser, et al.
Pageof 6